TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartellieri, Marc, Arndt, Claudia, Feldmann, Anja, von Bonin, Malte, Ewen, Eva-Maria, Koristka, Stefanie, Michalk, Irene, Stamova, Slava, Berndt, Nicole, Gocht, Anne, Bornhäuser, Martin, Ehninger, Gerhard, Schmitz, Marc, Bachmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909541/
https://www.ncbi.nlm.nih.gov/pubmed/24498554
http://dx.doi.org/10.4161/onci.26770
Descripción
Sumario:We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.

Ejemplares similares